Table 1 Summary of clinical studies of tendon-derived cell therapy
From: Challenges and perspectives of tendon-derived cell therapy for tendinopathy: from bench to bedside
Injuries | Duration of symptoms | Follow-up | Number of patients | Clinical outcome* | References |
|---|---|---|---|---|---|
Lateral epicondylitis | 29.24 months | 4.5 years | 16 | VAS 5.73 to 1.21 [78%] QuickDASH 45.88 to 6.61 [84%] UEFS 31.73 to 9.20 [64%] Grip strength score 19.85 to 46.60 [208%] MRI score 4.31 to 2.87 Patients satisfied with treatment 93% | [19] |
31 months | 1 year | 20 | VAS 5.94 to 0.76 QuickDASH 45.88 to 3.84 Grip strength score 20.17 to 37.38 MRI score 4.31 to 2.88 | [18] | |
Gluteal tendinopathy | 33 months | 2 years | 12 | VAS 7.2 to 3.1 OHS 24 to 38.9 SF-36 28.1 to 43.3 Patients satisfied with treatment 8/12 | [20] |
Rotator cuff tendinopathy | 12 months | 1 year | 1 | VAS 1 Oxford shoulder score 47 QuickDASH 13 MRI partial-thickness rim-rent tear not detectable | [34] |
4 months | 6 months | 1 | MRI score 5 to 1.33 Internal rotation strength 231-253 N Athlete returned to full training pain free and international level competition | [35] | |
Chronic pain with five-month acute exacerbation | More than 12 months | 1 | Completely symptom-free Complete range of movement and returned to golf game without limitation | [21] |